Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Bloom Burton & Co. Healthcare Investor Conference 2022
25 slides from Abcellera Biologics's conference presentation, May 2, 2022
Slide 1: Corporate Overview
CORPORATE OVERVIEW BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE COPYRIGHT © ABCELLERA May 2, 2022
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performance, or achievements to be Secu
Slide 3: We Are a Technology Company
WE ARE A TECHNOLOGY COMPANY CORPORATE OVERVIEW AbCellera was founded after spending more than 12 years working on technology for biomedical research. We wanted our work to really matter. COPYRIGHT © ABCELLERA We looked for the place where technology makes the difference. 3
Slide 4: Antibody Therapeutics Market
ANTIBODY THERAPEUTICS MARKET IMMUNOLOGY IS THE $170B CORPORATE OVERVIEW KILLER APP FOR FOR 10% CAGR for SINGLE-CELL 30+ YRS ANALYSIS 100+ approved drugs 40+ blockbusters COPYRIGHT © ABCELLERA 4
Slide 5: Illustrative Drug Development Investment Profile
Peak sales ILLUSTRATIVE DRUG DEVELOPMENT INVESTMENT PROFILE ~$1B LONG. EXPENSIVE. RISKY. CORPORATE OVERVIEW POS: >5% Technology intensive Years since 1y 2y 3y 4y 5y 6y 7y 8y 9y 10y 11y 12y 13y 14y 15y 16y 17y 18y 19y 20y 21y program start COPYRIGHT © ABCELLERA Stage of program Discovery to Phase 1 P
Slide 6: Technology as a Lever
TECHNOLOGY AS A LEVER TARGET TO IND IS ONE OF THE MOST COMPLEX & TECHNOLOGY INTENSIVE PATHS IN ANY SECTOR CORPORATE OVERVIEW 10 00 Target Drug +s Clinical te Identification Discovery ps Development regulations, technology, science, manufacturing, lab space, talent COPYRIGHT © ABCELLERA 6
Slide 7: How Did the Industry Get Here?
HOW DID THE INDUSTRY GET HERE? Market Value of therapeutic antibodies in 2025 300 Billion TECHNOLOGY FOR DISCOVERY HAS BEEN NEGLECTED CORPORATE OVERVIEW Muromonab-CD3 (Orthoclone OKT3) anti-CD3 for kidney transplantation rejection treatment Rituximab (Rituxan) anti-CD20 for Non-Hodgkin lymphoma Tras
Slide 8: Can It Be Built Better?
W E A S K E D O U R S E LV E S … Existing workflows are built unintentionally as a by-product of drug development, and are still based on workflows from the CORPORATE OVERVIEW 1980’s. CAN IT BE BUILT BETTER? If you make this your business, if you start from a clean slate and take advantage of modern
Slide 9: Is It Valuable?
W E A S K E D O U R S E LV E S … IS IT VALUABLE? + Accelerating approval of an + Drugging the undruggable CORPORATE OVERVIEW average antibody drug by 1 year could unlock >$100 billion in could be worth more than new market opportunities $200M in NPV + Being first to market could + Saving small biote
Slide 10: Our Strategy
O UR ST R AT EGY BE THE BEST IN THE WORLD 2x faster solve the unsolvable FROM TARGET TO IND highest quality unprecedented scale IND Engine CORPORATE OVERVIEW TECHNOLOGY COMPOSITION OF MATTER Patentable DNA sequence of the drug TARGETS IND SPECIFICATIONS SOFTWARE + Investigational New Drug Applicatio
Slide 11: Strategy Dictates the Business Model
STRATEGY DICTATES THE BUSINESS MODEL CORPORATE OVERVIEW Traditional Biotech Model AbCellera’s Business Model We are building a large diversified portfolio that we believe will generate Time 9-12 years 13 years long-term value and superior returns without Investment $900M LARGE investments in capabil
Slide 12: Why Isn't Anyone Doing This?
WHY ISN’T ANYONE DOING THIS? IT’S INCREDIBLY ~13 >$1 + HARD & CORPORATE OVERVIEW years billion UNFUNDABLE In hindsight, the honest pitch in No guarantees you can assemble the technology. 2012 to rebuild the front end of No guarantees can assemble the right people. biotech would have been… No guarant
Slide 13: Funding the Unfundable
FUNDING THE UNFUNDABLE OVER $900M IN EQUITY & NON-DILUTIVE CAPITAL CORPORATE OVERVIEW 2012 2014 2017 2018 2020 founded Closed ~$900K Approved funding Closed $10M Closed $105M Series A2 Seed Round for $30M DARPA Series A led P3 Project by DCVC Bio Approved funding for $126M Government of Canada Proje
Slide 14: COVID-19 Program
bamlanivimab COVID-19 PROGRAM U.S. FDA Authorization: November 2020 VALIDATED THE At the start of the COVID-19 pandemic in March 2020, AbCellera made a conscious decision to first prioritize speed in getting therapies out to patients. This resulted in the discovery of bamlanivimab, the first COVID-1
Slide 15: We're Investing in the Future
>$720M IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OTHERS ARE ~$500M CORPORATE OVERVIEW PULLING BACK. IN TECH DEVELOPMENT & ACQUISITIONS BY END OF 2022 WE’RE INVESTING IN THE FUTURE. 600K + SQ.FT. OF FACILITIES (total lab, office, & manufacturing spaces by 2024) 400+ COPYRIGHT © ABCELLERA EMPL
Slide 16: Where We Are: Our Tech Stack Today
W H E R E W E A R E : O U R T E C H STA C K TO D AY WE’VE CREATED A BEST-IN-WORLD TECHNOLOGY FROM DRUG TARGET TO LEAD CANDIDATE CORPORATE OVERVIEW 1 2 3 4 5 SOURCE SEARCH DECODE ANALYZE ENGINEER DELIVER immune responses millions of hundreds of hundreds to find a few the best from multiple immune cel
Slide 17: Data Accumulated
DATA ACCUMULATED SOURCE SEARCH DECODE ANALYZE ENGINEER CORPORATE OVERVIEW ENABLING TECHOLOGIES Optimized High-Throughput Automated Customized Protein Engineering Immunization Single-Cell Single-Cell Bioinformatics, & Multispecifics Screening Genomics & High-Throughput Development from any species, R
Slide 18: Where We're Going: Completing Our Tech Stack
WHERE WE’RE GOING: COMPLETING OUR TECH STACK FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT AbCellera Development Partner Development CORPORATE OVERVIEW 2012-2021: Antibody Discovery 2021-2024: Preclinical to IND Phase 1, 2, 3, Approval Tech Stack 1 2 3 4 5 Expansion into GMP / CMC Manufacturing
Slide 19: Unlocking New T Cell Engagers
UNLOCKING NEW T CELL ENGAGERS Enabled by the DRUG CLASSES following acquisitions: CORPORATE OVERVIEW CD3-binding antibodies OrthoMab WITH TECH Bispecific Platform Acquired in 2020 Recent acquisitions successfully integrated into GPCRs & ION CHANNELS Acquired in 2020 our tech stack are being leverage
Slide 20: Disclosed Partnerships
DISCLOSED PARTNERSHIPS PARTNERING WITH THE BEST DRUG DEVELOPERS OF ALL SIZES CORPORATE OVERVIEW We forge partnerships with large cap pharmaceutical companies, biotechnology companies of all sizes, and non-profit and government organizations through flexible deal structures: royalties & milestones eq
Slide 21: Illustrative Revenue Profile for One Successful Partnered Program
ILLUSTRATIVE REVENUE PROFILE FOR Key assumptions, hypothetical: $1.7 billion peak sales, no price inflation, no patient population growth, 5% royalty, 6 years to peak ONE SUCCESSFUL PARTNERED PROGRAM sales, 5 years at peak sales, US approval only AbCellera participation in programs is strongly weigh
Slide 22: Large Diversified Portfolio
LARGE DIVERSIFIED 58% oncology PORTFOLIO 17% neurology IN NEXT-GEN 6% immunology CORPORATE OVERVIEW 6% ophthalmology ANTIBODY 5% infectious disease 3% dermatology THERAPIES 50% 5% other human health, known Portfolio of 131 programs n = 65 with downstream participation is diversified COPYRIGHT © ABCE
Slide 23: Focussed on Key Value Drivers
FOCUSSED ON KEY VALUE DRIVERS CORPORATE OVERVIEW Probability Speed Portfolio Deal of Success Volume Structures Capture downstream value maximize the likelihood superior returns superior that suitable leads without the volatility and biophysical properties. risks COPYRIGHT © ABCELLERA faster workflow
Slide 24: We're a One-of-a-Kind Company with Familiar Themes
WE’RE A ONE-OF-A-KIND COMPANY WITH FAMILIAR THEMES CORPORATE OVERVIEW Build value through a Create a competitive Make long-term diverse portfolio of advantage through investments in future revenue vertical integration technology to streams accelerate development COPYRIGHT © ABCELLERA 24
Slide 25: Thank You
COPYRIGHT © ABCELLERA 25 CORPORATE OVERVIEW THANK YOU
AbCellera Biologics — Bloom Burton & Co. Healthcare Investor Conference 2022 on 6ix